Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies

Journal of Pathology

Volumn 223, Issue 2, 2011, Pages 263-274

  Aster, Jon C ^a   Blacklow, Stephen C ^b   Pear, Warren S ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

chromosomal rearrangements; Notch signalling; oncogene; T cell lymphoblastic leukaemia lymphoma; targeted therapy

Indexed keywords

NOTCH RECEPTOR; NOTCH1 RECEPTOR; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; NONHUMAN; PATHOGENESIS; PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 78649991073     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2789     Document Type: Review

References (130)

1. Kopan R, Ilagan MX,. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216-233.
2. Gordon WR, Vardar-Ulu D, Histen G, et al., Structural basis for autoinhibition of Notch. Nature Struct Mol Biol 2007; 14: 295-300.
3. Gordon WR, Vardar-Ulu D, L'Heureux S, et al., Effects of S1 cleavage on the structure, surface export, and signaling activity of human Notch1 and Notch2. PLoS ONE 2009; 4: e6613.
4. Logeat F, Bessia C, Brou C, et al., The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc Natl Acad Sci U S A 1998; 95: 8108-8112.
5. Rand MD, Grimm LM, Artavanis-Tsakonas S, et al., Calcium depletion dissociates and activates heterodimeric notch receptors. Mol Cell Biol 2000; 20: 1825-1835.
6. van Tetering G, van Diest P, Verlaan I, et al., Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem 2009; 284: 31018-31027.
7. Bozkulak EC, Weinmaster G,. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 2009; 29: 5679-5695.
8. Gordon WR, Roy M, Vardar-Ulu D, et al., Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood 2009; 113: 4381-4390.
9. Sorensen EB, Conner SD,. Gamma secretase-dependent cleavage initiates Notch signaling from the plasma membrane. Traffic 2010; 11: 1234-1235.
10. Lubman OY, Ilagan MX, Kopan R, et al., Quantitative dissection of the Notch: CSL interaction: insights into the Notch-mediated transcriptional switch. J Mol Biol 2007; 365: 577-589.
11. Del Bianco C, Aster JC, Blacklow SC,. Mutational and energetic studies of Notch 1 transcription complexes. J Mol Biol 2008; 376: 131-140.
12. Fryer CJ, Lamar E, Turbachova I, et al., Mastermind mediates chromatin-specific transcription and turnover of the Notch enhancer complex. Genes Dev 2002; 16: 1397-1411.
13. Oswald F, Tauber B, Dobner T, et al., p300 acts as a transcriptional coactivator for mammalian Notch-1. Mol Cell Biol 2001; 21: 7761-7774.
14. Wallberg AE, Pedersen K, Lendahl U, et al., p300 and PCAF act cooperatively to mediate transcriptional activation from chromatin templates by notch intracellular domains in vitro. Mol Cell Biol 2002; 22: 7812-7819.
15. Fryer CJ, White JB, Jones KA,. Mastermind recruits CycC: CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell 2004; 16: 509-520.
16. Hsieh JJ, Zhou S, Chen L, et al., CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci U S A 1999; 96: 23-28.
17. Kao HY, Ordentlich P, Koyano-Nakagawa N, et al., A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev 1998; 12: 2269-2277.
18. Oswald F, Winkler M, Cao Y, et al., RBP-Jkappa/SHARP recruits CtIP/CtBP corepressors to silence Notch target genes. Mol Cell Biol 2005; 25: 10379-10390.
19. Zhou S, Hayward SD,. Nuclear localization of CBF1 is regulated by interactions with the SMRT corepressor complex. Mol Cell Biol 2001; 21: 6222-6232.
20. Kuroda K, Han H, Tani S, et al., Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity 2003; 18: 301-312.
21. Sakano D, Kato A, Parikh N, et al., BCL6 canalizes Notch-dependent transcription, excluding Mastermind-like1 from selected target genes during left-right patterning. Dev Cell 2010; 18: 450-462.
22. Liefke R, Oswald F, Alvarado C, et al., Histone demethylase KDM5A is an integral part of the core Notch-RBP-J repressor complex. Genes Dev 2010; 24: 590-601.
23. Garg V, Muth AN, Ransom JF, et al., Mutations in NOTCH1 cause aortic valve disease. Nature 2005; 437: 270-274.
24. Li L, Krantz ID, Deng Y, et al., Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nature Genet 1997; 16: 243-251.
25. Oda T, Elkahloun AG, Pike BL, et al., Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nature Genet 1997; 16: 235-242.
26. McDaniell R, Warthen DM, Sanchez-Lara PA, et al., NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 2006; 79: 169-173.
27. Ellisen LW, Bird J, West DC, et al., TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66: 649-661.
28. Aster J, Pear W, Hasserjian R, et al., Functional analysis of the TAN-1 gene, a human homolog of Drosophila Notch. Cold Spring Harbor Symp Quant Biol 1994; 59: 125-136.
29. Pear WS, Aster JC, Scott ML, et al., Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996; 183: 2283-2291.
30. Allman D, Karnell FG, Punt JA, et al., Separation of Notch1 promoted lineage commitment and expansion/transformation in developing T cells. J Exp Med 2001; 194: 99-106.
31. Bellavia D, Campese AF, Checquolo S, et al., Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci U S A 2002; 99: 3788-3793.
32. Radtke F, Wilson A, Stark G, et al., Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999; 10: 547-558.
33. Pui JC, Allman D, Xu L, et al., Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999; 11: 299-308.
34. Weng AP, Ferrando AA, Lee W, et al., Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
35. Asnafi V, Buzyn A, Le Noir S, et al., NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009; 113: 3918-3924.
36. Breit S, Stanulla M, Flohr T, et al., Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006; 108: 1151-1157.
37. Larson Gedman A, Chen Q, Kugel Desmoulin S, et al., The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 2009; 23: 1417-1425.
38. Mansour MR, Sulis ML, Duke V, et al., Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009; 27: 4352-4356.
39. Park MJ, Taki T, Oda M, et al., FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009; 145: 198-206.
40. van Grotel M, Meijerink JP, Beverloo HB, et al., The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica 2006; 91: 1212-1221.
41. Zhu YM, Zhao WL, Fu JF, et al., NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 2006; 12: 3043-3049.
42. Aster JC, Pear WS, Blacklow SC,. Notch signaling in leukemia. Annu Rev Pathol 2008; 3: 587-613.
43. Tsuji H, Ishii-Ohba H, Ukai H, et al., Radiation-induced deletions in the 5′ end region of Notch1 lead to the formation of truncated proteins and are involved in the development of mouse thymic lymphomas. Carcinogenesis 2003; 24: 1257-1268.
44. Dumortier A, Jeannet R, Kirstetter P, et al., Notch activation is an early and critical event during T-cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol 2006; 26: 209-220.
45. O'Neil J, Calvo J, McKenna K, et al., Activating Notch1 mutations in mouse models of T-ALL. Blood 2006; 107: 781-785.
46. Lin YW, Nichols RA, Letterio JJ, et al., Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 2006; 107: 2540-2543.
47. Reschly EJ, Spaulding C, Vilimas T, et al., Notch1 promotes survival of E2A-deficient T cell lymphomas through pre-T cell receptor-dependent and -independent mechanisms. Blood 2006; 107: 4115-4121.
48. Mantha S, Ward M, McCafferty J, et al., Activating Notch1 mutations are an early event in T-cell malignancy of Ikaros point mutant Plastic/+ mice. Leuk Res 2007; 31: 321-327.
49. Maser RS, Choudhury B, Campbell PJ, et al., Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007; 447: 966-971.
50. Malecki MJ, Sanchez-Irizarry C, Mitchell JL, et al., Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol Cell Biol 2006; 26: 4642-4651.
51. Sulis ML, Williams O, Palomero T, et al., NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood 2008; 112: 733-740.
52. Chiang MY, Xu L, Shestova O, et al., Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 2008; 118: 3181-3194.
53. Kindler T, Cornejo MG, Scholl C, et al., K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood 2008; 112: 3373-3382.
54. Girard L, Hanna Z, Beaulieu N, et al., Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes Dev 1996; 10: 1930-1944.
55. Hoemann CD, Beaulieu N, Girard L, et al., Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia in c-myc transgenic mice. Mol Cell Biol 2000; 20: 3831-3842.
56. Shen H, Suzuki T, Munroe DJ, et al., Common sites of retroviral integration in mouse hematopoietic tumors identified by high-throughput, single nucleotide polymorphism-based mapping and bacterial artificial chromosome hybridization. J Virol 2003; 77: 1584-1588.
57. Howard G, Eiges R, Gaudet F, et al., Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 2008; 27: 404-408.
58. Tsuji H, Ishii-Ohba H, Katsube T, et al., Involvement of illegitimate V(D)J recombination or microhomology-mediated nonhomologous end-joining in the formation of intragenic deletions of the Notch1 gene in mouse thymic lymphomas. Cancer Res 2004; 64: 8882-8890.
59. Tsuji H, Ishii-Ohba H, Noda Y, et al., Rag-dependent and Rag-independent mechanisms of Notch1 rearrangement in thymic lymphomas of Atm(-/-) and scid mice. Mutat Res 2009; 660: 22-32.
60. Ashworth T, Pear W, Chiang MY, et al., Key role for a conserved internal translational start site in Notch1 in deletion-based mechanisms of Notch1 activation in T-ALL. Blood 2010; DOI 10.1182/blood-2010-05-286328.
61. Jeannet R, Mastio J, Macias-Garcia A, et al., Oncogenic activation of the Notch1 gene in T-ALL by deletion of its promoter. Blood 2010; DOI: 10.1182/blood-2010-05-286658.
62. Ji Y, Resch W, Corbett E, et al., The in vivo pattern of binding of RAG1 and RAG2 to antigen receptor loci. Cell 2010; 141: 419-431.
63. Sridharan R, Smale ST,. Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes. J Biol Chem 2007; 282: 30227-30238.
64. Kim J, Sif S, Jones B, et al., Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity 1999; 10: 345-355.
65. Kaplan CD, Laprade L, Winston F,. Transcription elongation factors repress transcription initiation from cryptic sites. Science 2003; 301: 1096-1099.
66. Tetzlaff MT, Yu W, Li M, et al., Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci U S A 2004; 101: 3338-3345.
67. Tsunematsu R, Nakayama K, Oike Y, et al., Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem 2004; 279: 9417-9423.
68. O'Neil J, Grim J, Strack P, et al., FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204: 1813-1824.
69. Thompson BJ, Buonamici S, Sulis ML, et al., The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204: 1825-1835.
70. Chiang MY, Xu ML, Histen G, et al., Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1. Mol Cell Biol 2006; 26: 6261-6271.
71. Malyukova A, Dohda T, von der Lehr N, et al., The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67: 5611-5616.
72. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al., c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20: 2096-2109.
73. Palomero T, Lim WK, Odom DT, et al., NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006; 103: 18261-18266.
74. Sharma VM, Calvo JA, Draheim KM, et al., Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol 2006; 26: 8022-8031.
75. Li X, Gounari F, Protopopov A, et al., Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. J Exp Med 2008; 205: 2851-2861.
76. Jarriault S, Brou C, Logeat F, et al., Signalling downstream of activated mammalian Notch. Nature 1995; 377: 355-358.
77. Dudley DD, Wang HC, Sun XH,. Hes1 potentiates T cell lymphomagenesis by up-regulating a subset of notch target genes. PLoS One 2009; 4: e6678.
78. Palomero T, Sulis ML, Cortina M, et al., Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Med 2007; 13: 1203-1210.
79. Ciofani M, Zuniga-Pflucker JC,. Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nature Immunol 2005; 6: 881-888.
80. Sade H, Krishna S, Sarin A,. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 2004; 279: 2937-2944.
81. Cullion K, Draheim KM, Hermance N, et al., Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009; 113: 6172-6181.
82. Chan SM, Weng AP, Tibshirani R, et al., Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007; 110: 278-286.
83. Gonzalez-Garcia S, Garcia-Peydro M, Martin-Gayo E, et al., CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7Rα gene expression in early human thymopoiesis and leukemia. J Exp Med 2009; 206: 779-791.
84. Barata JT, Cardoso AA, Boussiotis VA,. Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis? Leuk Lymphoma 2005; 46: 483-495.
85. Armstrong F, Brunet de la Grange P, Gerby B, et al., NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009; 113: 1730-1740.
86. Maillard I, Fang T, Pear WS,. Regulation of lymphoid development, differentiation, and function by the Notch pathway. Annu Rev Immunol 2005; 23: 945-974.
87. Hozumi K, Mailhos C, Negishi N, et al., Delta-like 4 is indispensable in thymic environment specific for T cell development. J Exp Med 2008; 205: 2507-2513.
88. Sambandam A, Maillard I, Zediak VP, et al., Notch signaling controls the generation and differentiation of early T lineage progenitors. Nature Immunol 2005; 6: 663-670.
89. Tan JB, Visan I, Yuan JS, et al., Requirement for Notch1 signals at sequential early stages of intrathymic T cell development. Nature Immunol 2005; 6: 671-679.
90. Krueger A, von Boehmer H,. Identification of a T lineage-committed progenitor in adult blood. Immunity 2007; 26: 105-116.
91. Bellavia D, Campese AF, Alesse E, et al., Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 2000; 19: 3337-3348.
92. Vilimas T, Mascarenhas J, Palomero T, et al., Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nature Med 2007; 13: 70-77.
93. Jin B, Shen H, Lin S, et al., The maml1 co-activator regulates constitutive NF-κB signaling and cell survival. J Biol Chem 2010; 285: 14356-14365.
94. Yashiro-Ohtani Y, He Y, Ohtani T, et al., Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A. Genes Dev 2009; 23: 1665-1676.
95. Nie L, Xu M, Vladimirova A, et al., Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J 2003; 22: 5780-5792.
96. Bailey AM, Posakony JW,. Suppressor of hairless directly activates transcription of enhancer of split complex genes in response to Notch receptor activity. Genes Dev 1995; 9: 2609-2622.
97. Nam Y, Sliz P, Song L, et al., Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 2006; 124: 973-983.
98. Nam Y, Sliz P, Pear WS, et al., Cooperative assembly of higher-order Notch complexes functions as a switch to induce transcription. Proc Natl Acad Sci U S A 2007; 104: 2103-2108.
99. Arnett K, Hass MR, McArthur DG, et al., Structural and mechanistic insights into cooperative assembly of dimeric notch transcription complexes. Nature Structural Mol Biol (in press).
100. Beverly LJ, Capobianco AJ,. Perturbation of Ikaros isoform selection by MLV integration is a cooperative event in Notch(IC)-induced T cell leukemogenesis. Cancer Cell 2003; 3: 551-564.
101. Chari S, Winandy S,. Ikaros regulates Notch target gene expression in developing thymocytes. J Immunol 2008; 181: 6265-6274.
102. Kathrein KL, Chari S, Winandy S,. Ikaros directly represses the notch target gene Hes1 in a leukemia T cell line: implications for CD4 regulation. J Biol Chem 2008; 283: 10476-10484.
103. Kleinmann E, Geimer Le Lay AS, Sellars M, et al., Ikaros represses the transcriptional response to Notch signaling in T-cell development. Mol Cell Biol 2008; 28: 7465-7475.
104. Dail M, Li Q, McDaniel A, et al., Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A 2010; 107: 5106-5111.
105. Marcais A, Jeannet R, Hernandez L, et al., Genetic inactivation of Ikaros is a rare event in human T-ALL. Leuk Res 2010; 34: 426-429.
106. Bellavia D, Mecarozzi M, Campese AF, et al., Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. EMBO J 2007; 26: 1670-1680.
107. Rohn JL, Lauring AS, Linenberger ML, et al., Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma. J Virol 1996; 70: 8071-8080.
108. Real PJ, Tosello V, Palomero T, et al., Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nature Med 2009; 15: 50-58.
109. Buonamici S, Trimarchi T, Ruocco MG, et al., CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009; 459: 1000-1004.
110. Palomero T, McKenna K, O'Neil J, et al., Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia 2006; 20: 1963-1966.
111. Wouters BJ, Jorda MA, Keeshan K, et al., Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007; 110: 3706-3714.
112. Ma X, Renda MJ, Wang L, et al., Rbm15 modulates Notch-induced transcriptional activation and affects myeloid differentiation. Mol Cell Biol 2007; 27: 3056-3064.
113. Mercher T, Raffel GD, Moore SA, et al., The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest 2009; 119: 852-864.
114. Mercher T, Cornejo MG, Sears C, et al., Notch signaling specifies megakaryocyte development from hematopoietic stem cells. Cell Stem Cell 2008; 3: 314-326.
115. Jundt F, Acikgoz O, Kwon SH, et al., Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia 2008; 22: 1587-1594.
116. Jundt F, Probsting KS, Anagnostopoulos I, et al., Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103: 3511-3515.
117. Saito T, Chiba S, Ichikawa M, et al., Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 2003; 18: 675-685.
118. Lee SY, Kumano K, Nakazaki K, et al., Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009; 100: 920-926.
119. Rosati E, Sabatini R, Rampino G, et al., Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009; 113: 856-865.
120. Schwarzmeier JD, Hubmann R, Duchler M, et al., Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2005; 46: 157-165.
121. Duechler M, Shehata M, Schwarzmeier JD, et al., Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia 2005; 19: 260-267.
122. Hubmann R, Schwarzmeier JD, Shehata M, et al., Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood 2002; 99: 3742-3747.
123. Phng LK, Gerhardt H,. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009; 16: 196-208.
124. Radtke F, Fasnacht N, Macdonald HR,. Notch signaling in the immune system. Immunity 2010; 32: 14-27.
125. Riccio O, van Gijn ME, Bezdek AC, et al., Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep 2008; 9: 377-383.
126. Aste-Amezaga M, Zhang N, Lineberger JE, et al., Characterization of notch1 antibodies that inhibit signaling of both normal and mutated notch1 receptors. PLoS One 2010; 5: e9094.
127. Li K, Li Y, Wu W, et al., Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J Biol Chem 2008; 283: 8046-8054.
128. Wu Y, Cain-Hom C, Choy L, et al., Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464: 1052-1057.
129. Moellering RE, Cornejo M, Davis TN, et al., Direct inhibition of the NOTCH transcription factor complex. Nature 2009; 462: 182-188.
130. van Grotel M, Meijerink JP, van Wering ER, et al., Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008; 22: 124-131.